Core Viewpoint - The approval of Praluent (普乐司兰钠) by the NMPA marks a significant advancement in the treatment of familial chylomicronemia syndrome (FCS) in China, filling a long-standing gap in the rare lipid metabolism disease sector and highlighting progress in RNA-targeted therapies for rare diseases [4][6]. Group 1: Drug Approval and Mechanism - Praluent is the first small interfering RNA drug targeting APOC3 mRNA, which plays a crucial role in lipid metabolism by inhibiting lipoprotein lipase activity, leading to elevated triglyceride levels in the blood [4]. - The drug has shown a remarkable efficacy, with fasting triglyceride levels decreasing by approximately 80% from baseline in FCS patients, and a similar reduction in the incidence of acute pancreatitis compared to placebo [6]. Group 2: Clinical Data and Treatment Burden - Clinical data indicates that Praluent requires administration only four times a year, significantly reducing the treatment burden and improving long-term medication adherence among patients [6]. - The global Phase III clinical trials confirm the safety and applicability of Praluent, showing no significant difference in overall adverse event rates compared to placebo, and a lower incidence of severe adverse events [7]. Group 3: Market Strategy and Future Potential - Sanofi's acquisition of development and commercialization rights for Praluent in Greater China from Arrowhead Pharmaceuticals reflects confidence in RNA drug platforms and the metabolic disease sector [6]. - The FDA has granted breakthrough therapy designation for Praluent for severe hypertriglyceridemia, indicating potential expansion beyond rare disease populations to a broader high-risk metabolic disorder patient base by December 2025 [6]. Group 4: Broader Implications for Metabolic Health - The approval of Praluent signifies a shift in lipid metabolism treatment from merely controlling indicators to precise regulation of key pathways, offering new therapeutic possibilities for complex metabolic disorders [7].

Core Insights - AstraZeneca and Ionis Pharmaceuticals have jointly developed Ipupronit Sodium Injection, which has been approved by the National Medical Products Administration for the treatment of adult patients with hereditary transthyretin amyloidosis polyneuropathy (ATTRv-PN) [1] - Ipupronit Sodium is the first and currently the only gene-silencing agent approved for the treatment of ATTRv-PN in China [1] Group 1: Disease Overview - ATTR is caused by the accumulation of misfolded TTR protein produced by the liver, leading to organ damage and failure, with various complications affecting cardiovascular, neurological, and renal health [2] - ATTR has multiple phenotypes, including ATTR-CM (primarily affecting the heart) and ATTRv-PN (primarily affecting the peripheral nervous system), with ATTRv-PN being a debilitating disease that can lead to motor function impairment within five years of diagnosis [2] - The average age of onset for patients in China is 42 years, with a range from 17 to 68 years, and there is a significant delay of 3 to 4 years from symptom onset to diagnosis due to low awareness among the public and healthcare professionals [2] Group 2: Treatment Insights - Ipupronit Sodium is a gene-silencing agent administered once a month, which works by upstream inhibition of TTR protein production, showing potential for treating various types of transthyretin amyloidosis [3] - The approval of Ipupronit Sodium provides new hope for ATTRv-PN patients, as clinical evidence indicates it can halt the progression of neuropathy and significantly improve neurological function and quality of life [3]